# A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT

> **NCT02065323** · PHASE2 · WITHDRAWN · sponsor: **Oscar Goodman, Jr.**

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Standard ADT
- **DRUG:** Dovitinib

## Key facts

- **NCT ID:** NCT02065323
- **Lead sponsor:** Oscar Goodman, Jr.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2014-08
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Terminated due to budgetary considerations and length of development.
- **Last updated:** 2015-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02065323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02065323, "A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02065323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*